GT199900069A - Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla. - Google Patents

Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla.

Info

Publication number
GT199900069A
GT199900069A GT199900069A GT199900069A GT199900069A GT 199900069 A GT199900069 A GT 199900069A GT 199900069 A GT199900069 A GT 199900069A GT 199900069 A GT199900069 A GT 199900069A GT 199900069 A GT199900069 A GT 199900069A
Authority
GT
Guatemala
Prior art keywords
gabapentine
prepare
pharmaceutical preparations
stabilized pharmaceutical
stabilized
Prior art date
Application number
GT199900069A
Other languages
English (en)
Inventor
Akira Aomatsu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15097118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT199900069(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT199900069A publication Critical patent/GT199900069A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polymerisation Methods In General (AREA)

Abstract

LA INVENCIÒN SE REFIERE A UNA PREPARACIÒN FARMACEUTICA ESTABILIZADA SÒLIDA O LÌQUIDA DEL DERIVADO DE ÀCIDO
GT199900069A 1998-05-15 1999-05-14 Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla. GT199900069A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13311398 1998-05-15

Publications (1)

Publication Number Publication Date
GT199900069A true GT199900069A (es) 2000-11-04

Family

ID=15097118

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199900069A GT199900069A (es) 1998-05-15 1999-05-14 Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla.

Country Status (37)

Country Link
US (1) US7309719B1 (es)
EP (1) EP1077692B1 (es)
JP (1) JP4612923B2 (es)
KR (1) KR100602047B1 (es)
CN (1) CN1303991C (es)
AR (1) AR020323A1 (es)
AT (1) ATE271864T1 (es)
AU (1) AU768277B2 (es)
BR (1) BR9910508B1 (es)
CA (1) CA2327285C (es)
CO (1) CO5021224A1 (es)
CR (1) CR6026A (es)
CU (1) CU23253B7 (es)
DE (1) DE69918977T2 (es)
DK (1) DK1077692T3 (es)
EG (1) EG26803A (es)
ES (1) ES2221385T3 (es)
GT (1) GT199900069A (es)
HK (1) HK1036586A1 (es)
HN (1) HN1999000072A (es)
HU (1) HU228771B1 (es)
ID (1) ID27724A (es)
IL (2) IL139298A0 (es)
IS (1) IS2233B (es)
MY (1) MY157878A (es)
NO (1) NO328959B1 (es)
NZ (1) NZ508015A (es)
PA (1) PA8472801A1 (es)
PE (1) PE20000556A1 (es)
PL (1) PL204921B1 (es)
PT (1) PT1077692E (es)
SI (1) SI1077692T1 (es)
SV (1) SV1999000064A (es)
TW (1) TWI243054B (es)
UY (1) UY25512A1 (es)
WO (1) WO1999059573A1 (es)
ZA (1) ZA200006484B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0934061T6 (en) 1996-07-24 2015-01-26 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
EP1430893A1 (en) * 2000-06-16 2004-06-23 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chloride ion
PT1289364E (pt) * 2000-06-16 2004-04-30 Teva Pharma Gabapentina estavel contendo mais do que 20 ppm de iao cloreto
KR100667721B1 (ko) * 2000-06-16 2007-01-15 테바 파마슈티컬 인더스트리즈 리미티드 제어 범위 내의 ｐｈ를 갖는 안정한 가바펜틴
EP1384473A1 (en) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chlorine ion
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
ATE334656T1 (de) * 2001-05-25 2006-08-15 Warner Lambert Co Flüssige pharmazeutische zusammensetzung
RU2340331C2 (ru) * 2004-02-04 2008-12-10 Алембик Лимитед Форма пролонгированного высвобождения венлафаксина гидрохлорида
EP1761255A1 (en) * 2004-05-17 2007-03-14 Odessa Pharma LLC Decreasing brain neuronal glutamate levels using alpha-keto branched chain amino acids
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
WO2007107835A2 (en) * 2006-03-17 2007-09-27 Aurobindo Pharma Limited Stable liquid formulations of antiepileptic agents
DE102007019071A1 (de) 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
EP2116618A1 (en) * 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
SG10201505101VA (en) * 2009-05-19 2015-07-30 Neuroderm Ltd Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
EP2389934A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Tablet Formulations of Pregabalin
TR201005241A1 (tr) 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
EP2389933A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Pregabalin Compositions
HUE037005T2 (hu) 2010-11-15 2018-08-28 Neuroderm Ltd L-dopának, dopa dekarboxiláz inhibitoroknak, katechol-O-metil transzferáz inhibitoroknak és ezekhez szolgáló kompozícióknak folyamatos bevezetése
ES2715028T3 (es) 2012-06-05 2019-05-31 Neuroderm Ltd Composiciones que comprenden apomorfina y ácidos orgánicos y sus usos
CN103494796B (zh) * 2013-09-30 2016-01-20 浙江华义医药有限公司 普瑞巴林稳定的药物组合物及其制备方法
EP3099288A1 (en) 2014-01-28 2016-12-07 Sun Pharmaceutical Industries Ltd Stabilized gastroretentive tablets of pregabalin
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US10022320B2 (en) 2014-03-13 2018-07-17 Neuroderm, Ltd. Dopa decarboxylase inhibitor compositions
WO2015144825A1 (en) * 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
MA39272A (fr) * 2014-04-09 2015-10-14 Arven Ilac Sanayi Ve Ticaret As Formulations à libération prolongée de gabapentine
CA2953225A1 (en) 2015-05-26 2016-12-01 Isa Odidi Controlled extended release pregabalin
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
CN113164423A (zh) 2018-10-04 2021-07-23 美德阿利克斯株式会社 用非水溶剂稳定化的制剂
US10792262B1 (en) * 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US20220296548A1 (en) 2019-10-25 2022-09-22 Kyoto University Preventative or therapeutic agent for tauopathy
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
CN112843015A (zh) * 2021-04-08 2021-05-28 海南鑫开源医药科技有限公司 一种加巴喷丁胶囊制剂及其制备方法
WO2023055457A1 (en) 2021-09-29 2023-04-06 Amneal Pharmaceuticals Llc Baclofen-containing granule formulations and reduced patient exposure to metabolite variations

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4126684A (en) 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4255448A (en) * 1979-09-10 1981-03-10 Wisconsin Alumni Research Foundation Method for reducing epileptiform activity
GB8311804D0 (en) * 1983-04-29 1983-06-02 Merrell Toraude & Co Treatment of seizure disorders and pharmaceutical compositions
US4595697A (en) * 1984-03-28 1986-06-17 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
CA1249968A (en) 1984-04-05 1989-02-14 Kazuo Kigasawa Ointment base
JPS63253022A (ja) * 1987-04-08 1988-10-20 Nitto Electric Ind Co Ltd バクロフエン外用製剤
PH26730A (en) * 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5006560A (en) * 1989-12-20 1991-04-09 Schering Corporation Use of GABA-B selective agonists as anti-tussive agents
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
EP0458751A1 (en) * 1990-05-25 1991-11-27 Warner-Lambert Company Delivery system for cyclic amino acids with improved taste, texture and compressibility
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
HUT59656A (en) * 1990-11-15 1992-06-29 Puetter Medice Chem Pharm Process for producing s/+/-phenyl-alkanoic acids and alpha-amino-acids containing complexes and pharmaceutical compositions containing them as active components
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
JPH0597703A (ja) * 1991-10-04 1993-04-20 Yamanouchi Pharmaceut Co Ltd 改変型組織プラスミノーゲン活性化因子含有組成物
DK0641330T3 (da) * 1992-05-20 2001-12-03 Univ Northwestern Gaba- og L-glutaminsyreanaloger til antikrampeanfaldsbehandling
US5629008A (en) * 1992-06-02 1997-05-13 C.R. Bard, Inc. Method and device for long-term delivery of drugs
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5248678A (en) * 1992-06-30 1993-09-28 Fractal Laboratories, Inc. Methods for increasing arousal and alertness and for the amelioration of comatose states
US5260337A (en) * 1992-07-29 1993-11-09 Merck & Co., Inc. Ibuprofen-muscle relaxant combinations
JP3467794B2 (ja) * 1993-03-09 2003-11-17 日本油脂株式会社 学習能向上剤
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
JPH0867636A (ja) * 1994-08-30 1996-03-12 Yamanouchi Pharmaceut Co Ltd 播種性血管内凝固症候群（ｄｉｃ）の予防治療薬
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
JPH1017476A (ja) * 1996-06-28 1998-01-20 Nippon Seiyaku Kk 敗血症用非経口製剤及びそれによる予防及び治療方法
WO1998003189A1 (en) * 1996-07-22 1998-01-29 Cognetix, Inc. Use of conantokins
DK0934061T6 (en) * 1996-07-24 2015-01-26 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
US5780431A (en) * 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
IT1311984B1 (it) * 1999-03-26 2002-03-22 Bioindustria Lab Italiano Medi Procedimento per la preparzione di gabapentin.
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
KR100958552B1 (ko) * 2001-06-11 2010-05-17 제노포트 인코포레이티드 Ｇａｂａ 유사체의 프로드러그, 이의 조성물 및 용도

Also Published As

Publication number Publication date
MY157878A (en) 2016-07-29
IS2233B (is) 2007-04-15
IS5666A (is) 2000-10-16
EP1077692B1 (en) 2004-07-28
CR6026A (es) 2008-08-26
PL344218A1 (en) 2001-10-08
CA2327285C (en) 2005-06-14
JP2000034226A (ja) 2000-02-02
NO20005768L (no) 2000-11-14
EG26803A (en) 2014-09-21
NZ508015A (en) 2003-11-28
PA8472801A1 (es) 2001-12-14
US7309719B1 (en) 2007-12-18
WO1999059573A9 (en) 2000-05-04
HUP0102022A2 (hu) 2001-11-28
ID27724A (id) 2001-04-26
KR20010043611A (ko) 2001-05-25
CN1303991C (zh) 2007-03-14
DK1077692T3 (da) 2004-12-06
HU228771B1 (en) 2013-05-28
HN1999000072A (es) 2000-06-05
EP1077692A1 (en) 2001-02-28
IL139298A (en) 2009-07-20
BR9910508B1 (pt) 2012-01-24
TWI243054B (en) 2005-11-11
NO20005768D0 (no) 2000-11-14
IL139298A0 (en) 2001-11-25
PE20000556A1 (es) 2000-08-10
CA2327285A1 (en) 1999-11-25
ZA200006484B (en) 2002-02-11
BR9910508A (pt) 2001-01-02
CU23253B7 (es) 2007-12-17
AU4073599A (en) 1999-12-06
DE69918977D1 (de) 2004-09-02
AU768277B2 (en) 2003-12-04
HUP0102022A3 (en) 2002-11-28
ES2221385T3 (es) 2004-12-16
JP4612923B2 (ja) 2011-01-12
CN1301155A (zh) 2001-06-27
CO5021224A1 (es) 2001-03-27
PT1077692E (pt) 2004-12-31
HK1036586A1 (en) 2002-01-11
NO328959B1 (no) 2010-06-28
SV1999000064A (es) 2000-03-31
SI1077692T1 (en) 2004-10-31
DE69918977T2 (de) 2005-07-28
KR100602047B1 (ko) 2006-07-19
UY25512A1 (es) 1999-07-19
AR020323A1 (es) 2002-05-08
PL204921B1 (pl) 2010-02-26
ATE271864T1 (de) 2004-08-15
WO1999059573A1 (en) 1999-11-25

Similar Documents

Publication Publication Date Title
GT199900069A (es) Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla.
AR012125A1 (es) UNA SAL DE UN COMPUESTO DERIVADO DEL ÁCIDO NAFTIRIDINA CARBOXíLICO , SU USO PARA LA FABRICACIoN DE UN MEDICAMENTO , PROCEDIMIENTO PARA PREPARARLA Y UNA COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE
DK0956858T3 (da) Farmaceutiske præparater indeholdende lactobacilli til behandling af vaginale infektioner
DK1149116T3 (da) Fremgangsmåde til fremstilling af multipelt tværbundne hyaluronsyrederivater
ES2187062T3 (es) Composiciones farmaceuticas que contienen proteina plasmatica.
HN1999000045A (es) Derivados biciclicos del acido hidroxamico
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
ES2145913T3 (es) Inhibidores de metaloproteasas.
CY1105771T1 (el) Φαρμακευτικες συνθεσεις εφαρμογης στον βλεννογονο
DE69940769D1 (de) Orale flüssige zusammensetzungen
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
ATE83374T1 (de) Neue galenische form von fenofibrat.
DK1024794T3 (da) Fremgangsmåde til behandling af kapsler og törre, pulveriserede farmaceutiske formuleringer
DE60126321D1 (de) Gelsystem zur ocularen verabreichung von arzneimitteln
ID23806A (id) Komposisi-komposisi farmasi untuk pemberian oral yang terdiri dari bahan aktif dan siklodekstrin
ES2144239T3 (es) Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
DE50010284D1 (de) Arzneimittel zur behandlung von bluthochdruck
IT1265101B1 (it) Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
BR9913782A (pt) Processo de preparação de uma formualação galênica que compreende fenofibrato como princìpio ativo, formulação galênica, medicamento e utilizações de um meio lìquido e de partìculas de fenofibrato
HUP0203339A2 (hu) Nyálkahártyára juttatandó, ciclesonidot tartalmazó gyógyászati készítmény
MX9306607A (es) Dindihidrogeno-otorfosfato de tilidina, procedimiento para su obtencion y las preparaciones farmaceuticas que lo contienen.
DZ2560A1 (fr) Préparations pharmaceutiques de cilansétrone stabilisées contre la racémisation.
GT199900062A (es) Preparados efervescentes.
BR9707083A (pt) Formas sólidas de administração com liberação instantánea e processos para a sua produção